European Best Practice Guidelines 1-4 Evaluating anaemia and initiating treatment

Publisher Website
Google Scholar
Abstract
And 26.4% of peritoneal dialysis patients. Table 11 Results summarizes the results by country, and some between- country variation is observed. Figure 3 presents aggreg- Key points from the EBPG ate findings for both cohorts of patients. In 35.1% of patients, the start of dialysis and initiation of epoetin $ Evaluate anaemia in chronic renal failure therapy were simultaneous. Only 7.9% of patients were (CRF ) patients when haemoglobin (Hb) is started on epoetin in the 6 months preceding dialysis, 6 months before' and '>6 months Hb is consistently 25% of haemodialysis patients and >30% of periton- eal dialysis patients started epoetin therapy with hae- As EBPG 1-3 are narrative guidelines for which no moglobin levels between 8 and 8.9 g/dl, and >25% of empirical support is available, the data reported here dialysis patients started treatment below 8 g/dl. These pertain mainly to EBPG 4 (1). They are complemented starting haemoglobin levels were consistent regardless with additional results that support the main issues in of the relationship between start of dialysis and initi- this cluster of guidelines. ation of epoetin therapy for both haemodialysis and The relationship between the start of dialysis and peritoneal dialysis patients (Figure 5). Some variability initiation of epoetin treatment was examined. As shown between Western European countries was observed in Figure 2, the patterns are different for haemodialysis

This publication has 0 references indexed in Scilit: